Understanding VEGF's role in angiogenesis has led to the development of therapeutic agents that modulate its activity. Anti-VEGF therapies, such as Bevacizumab, are used to inhibit angiogenesis in cancer treatment. Conversely, VEGF therapy is being explored for treating ischemic diseases by promoting blood vessel formation. Histological assessment is crucial in evaluating the efficacy and safety of these therapies by examining changes in vascularization within treated tissues.
